Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 (adaptive design): icovamenib in patients with insulin deficient type 2 diabetes (HbA1c ≥8.5% and BMI <32 kg/m2), uncontrolled at baseline on current antidiabetic medication

Next Previous
Trial Profile

Phase 2/3 (adaptive design): icovamenib in patients with insulin deficient type 2 diabetes (HbA1c ≥8.5% and BMI <32 kg/m2), uncontrolled at baseline on current antidiabetic medication

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 08 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icovamenib (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 08 Apr 2024 New trial record
  • 01 Apr 2024 According to Biomea Fusion media release, Data readouts of COVALENT-111 and COVALENT-112 in 2024 will inform the design of potentially pivotal Phase 3 studies in type 2 and type 1 diabetes, targeting 2025 initiation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top